INTRODUCTION
============

Among occupational lung diseases, the most prevalent diseases are induced by inhalation of dust, including asbestos, crystalline silica, and coal. Inhalation of these types of dust may result in development of a variety of pulmonary diseases, such as a nodular interstitial lung disease,progressive massive fibrosis (PMF) , emphysema, and classical pneumoconiosis, including coal workers pneumoconiosis (CWP) [@B050] . Exposure to silica and coal mine dust may also result in pulmonary scarring in a pattern that mimics idiopathic pulmonary fibrosis, and in chronic obstructive pulmonary disease (COPD) , including emphysema and chronic bronchitis, which appears indistinguishable from obstructive lung disease caused by exposure to tobacco smoke. Exposure to coal mine and silica dust may therefore result in restrictive, obstructive, or mixed patterns of impairment on pulmonary function testing. Many researchers are aware of the nodular fibrosis pulmonary tissue reactions in response to retained dust; however, they may not realize that these other reactions of the pulmonary parenchyma and airways to dust exist and can result in significant respiratory dysfunction in sensitive individuals. Fibrosis of tissue resulting from these types of dust may invoke functional damage and irreversible change [@B013] . Notably, crystalline silica has been classified as a class I carcinogen by the International Agency for Research on Cancer [@B029] .

Pneumoconiosis is a lung disease caused by inhalation of mine dust. Diagnosis of pneumoconiosis depends on morphological changes by radiological findings and functional change by pulmonary function test. Unfortunately, there is no cure for the damage and current diagnostic findings are only limited to fibrosis in the lung, which is usually irreversibly progressive. Once silica threshold has been exceeded, silica-induced pulmonary disease may progress without further exposure to silica. Therefore, it is important that research on potential and prospective biomarkers for pneumoconiosis should be conducted prior to the occurrence of irreversible radiological changes in the lung [@B024]; [@B047] . Many researchers have studied biomarkers in pulmonary inflammation resulting from mineral dust [@B058] .

Detection of inflammatory biomarkers for pulmonary diseases involves invasive techniques, such as blood, bronchoalveolar lavage fluid (BALF) , and induced sputum. Because invasiveness sampling procedures to obtain specimens may induce an inflammatory response, non-invasive techniques,such as exhaled breath condensate (EBC) and exhaled air have been developed. Analyses of various biomarkers in exhaled breath have allowed non-invasive monitoring of inflammation and oxidative stress in respiratory tract in inflammatory lung diseases [@B023]; [@B035]; [@B022]; [@B025]; [@B039]; [@B031] . Studies of reactive oxygen species (ROS) using direct analysis of free radicals in EBC of patients with fibrosis have been reported [@B049] .

pH and fractional exhaled nitric oxide (FE~NO~) are simple and technically validated biomarkers studied in exhaled air [@B023]; [@B026] . The pH of EBC has been found to be lower in many respiratory disorders, including COPD [@B034]; [@B009] , asthma [@B023]; [@B028] , bronchoectasis [@B034] , and chronic cough [@B042] than in normal subjects. Therefore, many researchers have suggested that the pH of EBC could be useful a biomarker for detection of inflammatory acidification in the respiratory tract [@B023]; [@B026] . Exhaled NO released from lung cells, including inflammatory cells, epithelial cells, and endothelial cells in the respiratory tract has been known to be an effective biomarker in diagnosis and treatment of lung disorders and correlated with decrease of pulmonary function [@B046]; [@B037] . Reported lung disorders associated with the levels of FE~NO~ include asthma [@B032] and COPD [@B019] . Yet, there have been no reports on EBC in lung disorders that affect Korean patients. The objective of this study was to investigate the relationship between EBC pH or FE~NO~ as inflammatory biomarkers and pneumoconiosis findings obtained from radiological findings identified by the pneumoconiosis review committee and pulmonary function test (PFT) .

MATERIALS AND METHODS
=====================

Subjects.
---------

The study population included 120 retired male miners exposed to coal dust. Data on EBC, urine, chest x-ray, and PFT were obtained from the subjects. Personal information on age, body weight, height, and various personal histories (job, smoking status, and disease) was obtained using a structured questionnaire. The Research Ethics Committee of our institute approved the study protocol, and all participants gave informed written consent.

Collection of EBC.
------------------

Collection of EBC was performed in accordance with recommended guidelines of the American Thoracic Society [@B025] . Briefly, all participants rinsed their mouths with purified saline prior to collection. Exhaled breath condensate was collected during oral tidal breathing using the Rtube^TM^ EBC collection system (Respiratory Research Inc, USA) . All samples were collected for 10 minutes, and nose clips were worn. The condensate was transferred from the collection tube into cryogenic vials and stored at -80℃ until assay.

Measurement of EBC pH.
----------------------

The pH of EBC was assayed with a glass microelectrode (Orion 4Star/9802BN electrode, Orion, USA) after gas standardization through bubbling 150 μL of EBC with purified argon (99.99% \<) for 8 min, as previously described [@B001] .

Measurement of FE~NO~.
----------------------

Measurement of exhaled NO was performed as recommended by the American Thoracic Society/European Respiratory Society guidelines [@B002] . Briefly, FE~NO~ was measured with an NO analyzer (Sievers 280i, GE Analytical Instruments Inc., USA) . While wearing nose clips, participants performed continuous inhalation of nitric oxide free air and exhaled against a positive pressure of 16 mmH~2~O for longer than 6 seconds and generated expiratory flow of 50 mL/sec.

Analysis of urinary cotinine.
-----------------------------

Analysis of urinary cotinine, metabolite of nicotine, was measured by high performance liquid chromatography (HPLC, Agilent 1200 series; Agilent, USA) , as previously described [@B052] . Briefly, 3 mL of the urine samples and standard were added with 1 mL of 2 N sodium hydroxide. After mixing, 2 mL of dichloromethane was added and was centrifuged at 3,000 rpm for 10 min. After evaporation under nitrogen flow, suspended samples and standards with 800 μL of deionized water and 20 μL of suspended sample were injected into the HPLC. Cotinine was separated on a C18 column (150 × 4.6 mm, 3.5 μ; Agilent, USA) . Detecting wavelength was 260 nm.

PFT.
----

Using a spirometer (Vmax22, SensorMedics, USA) , PFT was performed in accordance with recommended guidelines of the American Thoracic Society/European Respiratory Society Task Force [@B011] .Forced vital capacity (FVC) , which is the volume delivered during an expiration made as forcefully and completely as possible starting from full inspiration, forced expiratory volume in one second (FEV~1~) , which is the volume delivered in the first second of an FVC maneuver, and FEV1/FVC ratio (%FEV~1~/FVC) were measured and calculated for predicted volume by the regression equation of Morris *et al*. (1971) .

1.  FVC predicted volume (L) = 0.148 × height (in)

2.  \- 0.025 × age (yr) - 4.241

3.  FEV~1~ predicted volume (L) = 0.092 × height (in)

4.  \- 0.032 × age (yr) - 1.26

5.  Predicted percentages (%) of FVC (%FVC) and FEV~1~ (%FEV~1~) were calculated by the following equation:

6.  \% predicted = measured volume (L) /predicted volume (L) × 100

PFT was performed with the patient in the sitting position via the closed circuit method, measuring inhaled and exhaled air during the same test cycle. Tests were conducted until gaining 3 adequate sets of data.

Chest x-ray.
------------

Radiological findings for pneumoconiosis were observed on digital chest x-ray (Digital Diagnost, Philips, Netherlands) . Diagnosis of pneumoconiosis was identified by the pneumoconiosis review committee of the Korea Worker's Compensation & Welfare Service, and classifications were categorized in accordance with classification of [@B030] .

Statistical analysis.
---------------------

Data were analyzed using SPSS 14.0 (SPSS, Chicago, IL, USA) . General characteristics and PFT data showed normal distribution, whereas FE~NO~ showed log-normal distribution (Kolmogorov-Smirnov test) ; therefore, data on FE~NO~ was log-transformed for all of the statistical tests, and the results were expressed as the geometric mean (GM) and geometric standard deviation (GSD) . EBC pH did not show normal or log-normal distribution; therefore, data on EBC pH was analyzed by nonparametric statistics. A *p*-value of \< 0.05 (two-tailed) was considered significant for all of the tests.

RESULTS
=======

General characteristics of the study populations.
-------------------------------------------------

Number of study subjects classified by the ILO categories of pneumoconiosis [@B030] was "small opacity" in 62 (51.6%) , type I in 44 (36.6%) , type II or III in 18 (15.0%) , and "large opacity" in 17 (14.2%) ([Table 1](#T001){ref-type="table"}) .

Characteristics of the study populations are shown in [Table 2](#T002){ref-type="table"}. Average age in the control group (n = 41) , the small opacity group (n = 62) , and the large opacity group (n = 17) were 60.9 ± 8.8, 64.2 ± 7.5, and 65.3 ± 6.6 years, respectively. Percent of FEV~1~ in pneumoconiosis with large opacity (74.2 ± 18.1%) was lower than those of the control (86.5 ± 20.1%) and small opacity (87.8 ± 19.3% (*p* = 0.037) .Levels of BMI, %FVC, %FEV~1~, and number of smokers did not show significant statistical differences among the pneumoconiosis groups.

###### 

Numbers of each pneumoconiosis category according to the ILO classification

  ------------------- ---- ------ -----------------------------------------
  ILO category\*      N    ％     Profusion (N)
                                  
  Control             41   34.2   0/0 (34) ; 0/1 ( 7)
  Pneumoconiosis      79   65.8   
      Small opacity   62   51.6   
             I        44   36.6   1/0 (16) ; 1/1 (19) ; 1/2 (9)
          II, III     18   15.0   2/1 (10) ; 2/2 ( 6) ; 2/3 (1) ; 3/2 (1)
      Large opacity   17   14.2   A (17)
  ------------------- ---- ------ -----------------------------------------

###### 

General characteristics of the study subjects

  ----------------------------- ------------------ ------------------------ ------------------------ ----------
                                Control (n = 41)   Pneumoconiosis           p-values                 
                                                                                                     
                                                   Small opacity (n = 62)   Large opacity (n = 17)   
                                                                                                     
  Age (yrs)                     60.9 ± 8.8         64.6 ± 7.5               65.3 ± 6.6               0.042^a^
  BMI (kg/m^2^)                 24.1 ± 2.3         23.7 ± 2.6               23.1 ± 2.3               0.354^a^
  Exposure period (yrs)         14.4 ± 6.5         18.4 ± 7.7               16.9 ± 7.0               0.025^a^
  FVC (L)                       3.50 ± 0.78        3.36 ± 0.69              3.01 ± 0.64              0.063^a^
  FVC, ％ predicted             87.0 ± 18.6        89.3 ± 19.0              80.7 ± 18.5              0.250^a^
  FEV (L)                       2.50 ± 0.67        2.33 ± 0.53              1.95 ± 0.44              0.004^a^
  FEV~1~, ％ predicted          86.5 ± 20.1        87.8 ± 19.3              74.2 ± 18.1              0.037^a^
  FEV~1~/FVC ratio (％)         71.8 ± 12.3        69.6 ± 8.6               65.3 ± 10.1              0.088^a^
  Smoking, N (％)                                                                                    
                   Never        7 (17.1)           5 (8.1)                  2 (11.8)                 0.120^b^
                   Past         11 (26.8)          32 (51.6)                7 (41.1)                 
                   Current^c^   23 (56.1)          25 (40.3)                8 (47.1)                 
  ----------------------------- ------------------ ------------------------ ------------------------ ----------

†Mean ± SD

^a^Calculated by ANOVA test

^b^Calculated by χ^2^-test

^c^Urinary cotinine levels of self-reported non-smokers (2 cases) and past-smokers (7 cases) were greater than 785 μg/g creatinine (data not showed) , which was the lower limit of the confidence interval in self-reported current smokers, the selected cut-off level for identification of current smokers, and they were biochemically classified as current smokers

Levels of EBC pH and FE~NO~ according to general characteristics.
-----------------------------------------------------------------

No significant differences were observed between median of EBC pH and general characteristics,such as age, BMI, exposure period, smoking status, and criteria levels of %FVC, %FEV~1~, and %FEV~1~/FVC ([Table 3](#T003){ref-type="table"}) . The mean concentration of FE~NO~ in current smokers was lower than that in non smokers (never or past smokers) (*p* = 0.027) ([Fig. 1](#F001){ref-type="fig"}) , and the mean concentration of FE~NO~ in the low percentage FEV~1~ (\< 80%) was lower than that in the high percentage (80% ≤) (*p* = 0.023) . However, no significant differences were observed between the mean concentration of FE~NO~ and other general characteristics, including age, BMI, exposure period, and criteria levels of %FVC and %FEV~1~/FVC.

###### 

Concentrations of EBC pH and FE~NO~ according to general characteristics

  ----------------------- -------- ---------------- ------------- ---------------- ------------- ------------
  Characteristics                  N                EBC pH        FE~NO~                         
                                                                                                 
                                                    AM (Median)   Range            GM (GSD) \*   95％ CI
                                                                                                 
  Age (yrs)                  -59   36               7.94 (8.11)   5.71\~8.51       18.7 (1.4)    16.6\~21.1
  60-69                   56       7.99 (8.02)      6.42\~8.58    19.2 (1.6)       17.0\~21.6    
  70-                     \>28     7.73 (7.95)      5.41\~8.33    23.2 (1.6)       19.3\~28.0    
                                   *P* = 0.088^a^                 *P* = 0.090^c^                 
  BMI (kg/m^2^)           \< 25    83               7.91 (8.02)   5.41\~8.58       19.4 (1.5)    17.7\~21.2
  25                      37       7.93 (7.97)      5.71\~8.50    21.1 (1.6)       18.2\~24.5    
                                   *P* = 0.689^b^                 *P* = 0.647^d^                 
  Exposure period (yrs)      -9    20               8.02 (8.08)   7.60\~8.28       18.8 (1.4)    15.8\~22.3
  10-19                   55       7.96 (8.01)      5.71\~8.58    19.7 (1.5)       17.6\~22.2    
  20-                     45       7.82 (7.96)      5.41\~8.46    20.6 (1.6)       18.0\~23.3    
                                   *P* = 0.811^a^                 *P* = 0.710^c^                 
  Smoking status          Never    14               7.84 (7.95)   5.76\~8.38       24.4 (1.4)    20.0\~29.8
  Past                    50       8.06 (8.06)      7.18\~8.58    21.0 (1.6)       18.6\~23.8    
  Current                 56       7.81 (7.98)      5.41\~8.51    18.0 (1.5)       16.1\~20.1    
                                   *P* = 0.125^a^                 *P* = 0.027^c^                 
  ％FVC predicted         80 ≤     84               7.91 (8.01)   5.41\~8.58       20.1 (1.5)    18.4\~22.0
  \< 80                   36       7.92 (8.01)      5.76\~8.51    19.4 (1.6)       16.4\~22.9    
                                   *P* = 0.705^b^                 *P* = 0.654^d^                 
  ％FEV~1~ predicted      80 ≤     74               7.94 (8.01)   5.71\~8.58       21.3 (1.4)    19.6\~23.2
  \< 80                   46       7.88 (8.00)      5.41\~8.51    17.8 (1.6)       15.4\~20.6    
                                   *P* = 0.998^b^                 *P* = 0.023^d^                 
  ％FEV~1~/FVC ratio      70 ≤     66               7.93 (8.06)   7.89 (7.99)      20.9 (1.5)    19.1\~23.0
  \< 70                   54       7.89 (7.99)      5.41\~8.46    18.7 (1.6)       16.4\~21.3    
                                   *P* = 0.363^b^                 *P* = 0.153^d^                 
  ----------------------- -------- ---------------- ------------- ---------------- ------------- ------------

\*Geometric mean (Geometric standard deviation) , 95％ confidence interval, Unit: ppb

^a^Calculated by Kruskal-Wallis H test

^b^Calculated by Mann-Whitney U test

^c^Calculated by ANOVA test

^d^Calculated by t-test

Levels of EBC pH and FE~NO~ according to ILO categories of pneumoconiosis.
--------------------------------------------------------------------------

Levels of EBC pH and FE~NO~ did not show statistical differences among the pneumoconiosis groups (small or large opacity) , and the levels of EBC pH and FE~NO~ did not show statistical difference among the groups (ILO category II or III) in pneumoconiosis patients with small opacity ([Table 4](#T004){ref-type="table"}\~[5](#T005){ref-type="table"}) .

![EBC pH and FE~NO~ according to smoking status.](toxicr-26-329-g001){#F001}

###### 

Levels of EBC pH of pneumoconiosis patients

  ------------------- ----------- -------- -------- -------- ------------ --------------- -------
  Pneumoconiosis      N           AM ^a^   Median   Range    Mean rank    *p*-values^b^   
                                                                                          
  Opacity             Control     41       7.85     7.93     5.71\~8.46   53.8            
                      Small       62       7.93     8.02     6.42\~8.51   62.8            0.264
                      Large       17       8.00     8.03     5.41\~8.58   68.3            
  ILO Categories^c^   0           41       7.85     7.93     5.71\~8.46   47.4            
                      I           44       7.92     \>8.08   5.41\~8.58   57.9            0.223
                      II or III   18       7.95     7.97     7.57\~8.28   48.1            
  ------------------- ----------- -------- -------- -------- ------------ --------------- -------

^a^Arithmetic mean, arithmetic standard deviation

^b^Calculated by Kruskal-Wallis H test

^c^Subjects except for patients with large opacity ILO Categories (0: 0/0, 0/1; I: 1/0, 1/1, 1/2; II: 2/1, 2/2, 2/3, III: 3/2)

###### 

Levels of FE~NO~ of pneumoconiosis patients

  ------------------- ----------- ------- ------ --------- --------------- -------
  Pneumoconiosis      N           GM^a^   GSD    95％ CI   *P*-values^b^   
                                                                           
  Opacity             Control     41      21.1   1.5       18.6\~23.9      
                      Small       62      20.2   1.6       18.0\~22.7      0.264
                      Large       17      16.4   1.4       13.6\~19.7      
  ILO Categories^c^   0           41      21.1   1.5       18.6\~23.9      
                      I           44      20.0   1.6       17.3\~23.2      0.847
                      II or III   18      20.8   1.5       17.1\~5.2       
  ------------------- ----------- ------- ------ --------- --------------- -------

^a^Geometric mean, geometric standard deviation, unit: ppb

^b^Calculated by ANOVA test

^c^Subjects except for patients with large opacity ILO Categories (0: 0/0, 0/1; I: 1/0, 1/1, 1/2; II: 2/1, 2/2, 2/3, III: 3/2)

Relationship between FE~NO~ levels and associated variables.
------------------------------------------------------------

As shown in [Table 6](#T006){ref-type="table"}, FE~NO~ was significantly correlated with %FEV1 (β = 0.289, *p* = 0.001) , smoking status (β = -0.232, *p* = 0.008) , and BMI (β = 0.227, *p* =0.010) (adjusted R^2^ = 0.141, *p* \< 0.001) in the stepwise multiple regression analysis.

DISCUSSION
==========

Toxicity of crystalline silica and coal dust are based on activation of macrophages and lung inflammation. Many researchers have shown concern with regard to crucial mediators of the pulmonary disorder resulting from these mineral dusts [@B050] . Inhaled dusts or other transitional metals, including iron, copper, and vanadium have been known to induce ROS generated from activated phagocytes in the lung [@B005]; [@B012]; [@B015]; [@B051];[@B053]; [@B055]; [@B057] .

###### 

Stepwise multiple regression analysis of log (FE~NO~) against associated variables

  ------------------- -------------------- ------- -------- ------------
  Variables           B^a^                 SE      β        *p*-values
                                                            
  Intercept           0.704                0.179            0.000
  BMI                 0.017                0.006   0.227    0.010
  Smoking status^b^   −0.086               0.032   −0.232   0.008
  ％FEV1 predicted    0.003                0.001   0.289    0.001
  R^2^                0.162                                 
  Adjusted R^2^       0.414                                 
  F                   7.485 (p \< 0.001)                    
  ------------------- -------------------- ------- -------- ------------

^a^B: regression coefficients, SE: standard error, β: standardized B

^b^Dummy variable: yes or no Exclusion variables: age, work period, pneumoconiosis (dummy variable) , ％FVC predicted, ％FEV~1~/FVC ratio, EBC pH, urinary cotinine (log transformed)

Various harmful materials, including carcinogens and factors of oxidative stress are present in cigarettes [@B048] . Smoking status has been an important variable in epidemiology studies, especially occupational lung diseases, including pneumoconiosis [@B004]; [@B044]; [@B040]; [@B043] . Selfreports rely on participant's answers, which may be suspect due to hiding of their smoking habits. Cotinine is the major degradation product of nicotine metabolism [@B050] . Biological cotinine level has been established as a useful biological indicator of actual smoking status. Information on smoking status from face-to-face interviews was compared with laboratory urinary cotinine levels. Urinary cotinine levels of self-reported non-smokers (2 cases) and past-smokers (7 cases) were greater than 785 μg/g creatinine, which was the lower limit of the confidence interval in self-reported current smokers, the selected cut-off level for identification of active smokers. Therefore, they could be biochemically classified as current smokers. Discrepancy was observed between smoking status using self-reported and identification using urinary cotinine. Therefore, simultaneous estimation of biological indicators and self-reports for cigarette smoking were necessary for health surveillance, especially in the status encouraging prohibition of smoking or compensation for the disability of life.

Pneumoconiosis is the most prevalent lung disease showing decrease of pulmonary function (Schins and Borm,1999) . In this study, mean of %FEV1 of CWP patients with large opacity (74.2 ± 18.1%) was significantly higher than those of the control (86.5 ± 20.12%) and CWP patients with small opacity (87.8 ± 19.3%) (*p* = 0.037) .

Similar to biomarkers found in blood and urine, breathing analysis such as EBC, could be a promising non-invasive biomarker for detection of respiratory diseases as well systemic diseases. EBC has been studied in a variety of diseases, including asthma, COPD, cystic fibrosis, allergic rhinitis, and lung cancer [@B023] . EBC can be collected by cooling or freezing exhaled air, thereby condensing vapor and aerosolized droplets emerging with the breath [@B003] .

In this study, measurement of EBC pH was performed after bubbling argon gas for 8 min for removal of CO~2~,because measurement of EBC pH after dearation for removal of CO~2~ is a more validated technique [@B034]; [@B056] . Deaeration caused a significant increase in EBC pH, with a mean change of 2.10 (from 5.91 to 8.01) (results not shown) , which is similar to previous reports [@B008]; [@B042] .Median pH of EBC in total subjects in this study was 8.01 (range 5.41\~8.58) , which is similar to previous studies [@B045]; [@B058] .

Acidification occurs in several respiratory diseases [@B007]; [@B026]; [@B025] . The level of EBC pH is unaffected by variables that include subject age, race, gender, collecting and storage temperature, acute airway obstruction, ammonia in the mouth, saliva pH, hyperand hypoventilation [@B006]; [@B045]; [@B009]; [@B058]; [@B056] . Acidification of EBC occurs in acidic materials generated from inflammatory cells [@B027] , and gastroesophageal reflux [@B018] . Many researchers have suggested that EBC pH is a simple, reproducible, and relevant biomarker of disease [@B026]; [@B056] . However, in this study, there were no significant differences between EBC pH and measured variables, including general characteristics, criteria levels of pulmonary function test, and radiological findings for pneumoconiosis. [@B017] reported that EBC pH may not be a reliable marker of airway acidification, because EBC acidification can be affected by the balance of volatile salivary acids and bases. [@B041] also reported that there were no significant relationships between EBC pH and PFT and bronchitis. Thus, [@B007] suggested that more research on the relationship between EBC pH and pulmonary inflammation would be necessary.

FE~NO~ in association with asthma and has been extensively investigated and has been shown to correlate with predominantly eosinophilic airway inflammation and to be reduced by corticosteroid therapy [@B032];[@B033] . In this study, mean concentrations of non-smokers, non-pneumoconiosis, and non-COPD subjects were 24.4 ppb, 21.1 ppb, and 20.9 ppb, respectively. These results, which are lower than the mean concentration (26 ppb) of the control studied by [@B021] , are higher than that (17.8 ppb) of the non-smoking control studied by [@B016] .

In this study, we found that FE~NO~ in smokers (18.0 ppb) was lower than in either never-smokers (24.4 ppb) or pastsmokers (21.0 ppb) (p = 0.027) , and that the levels of FE~NO~ showed a statistical relationship among smoking status (β =-0.232, p = 0.008) . These results are in agreement with those of previous studies [@B016]; [@B036]; [@B010] . The explanation for these results could be that decreased exhaled NO in smokers is the result of muscular, structural, and metabolic damage resulting from alterations of skeletal muscle, such as oxidative fiber atropy, increased glycolic capacity, and reduced expression of the constitutive NO synthase [@B038] , or may be due to the effect of tobacco smoking, which down-regulates epithelial NO synthase, and may reflect increased oxidative stress that may consume NO in formation of peroxynitrite [@B031] .

Exposure to coal mine dust may result in COPD, including emphysema and chronic bronchitis, that appears indistinguishable from obstructive lung disease. Coal mine and silica dust may therefore result in restrictive, obstructive, or mixed patterns of impairment on pulmonary function testing [@B013] . In this study, no significant differences in FE~NO~ were observed among radiological findings for pneumoconiosis. The mean concentration of FE~NO~ in the low percentage FEV~1~ (\< 80%) was lower than that in the high percentage (80% ≤) (*p* = 0.023) . However, there were no significant differences between the mean concentration of FE~NO~ and criteria levels of %FEV~1~/FVC, which is another criteria index for COPD. The explanation for these results may be that radiological findings or decreased PFT are the results of inflammation or fibrosis in the lung; however, FE~NO~ results from the current response of oxidative stress due to inflammation or exposure to hazardous materials. Another possibility may be that PFT is affected by differences in the anatomy of the respiratory tract, such as restriction of bronchus. Conventionally measured FE~NO~ in COPD is less useful, since the levels are usually normal or slightly elevated, except during exacerbations [@B032]; [@B010] . New techniques for measurement of exhaled NO have recently been extended by measurements of exhaled NO at different flows [@B016]; [@B014]; [@B020]; [@B054] .

In conclusion, no significant relationship was observed between the level of EBC pH and FE~NO~ and radiological findings and PFT. It was necessary to monitor the effects between exhaled biomarkers and pneumoconiosis progression, including decreasing PFT and exacerbation of radiological findings. Future studies will be required for investigation of more specific and sensitive biomarkers that are present in pneumoconiosis patients using new analytical techniques such as proximal and peripheral NO analysis.
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